Table 1 Clinical characteristics at baseline and activity of rheumatoid arthritis before and after therapy
Patient characteristics | Abatacept group | Tocilizumab group |
|---|---|---|
Number of patients | 10 | 10 |
Age; yr, mean ± SD | 59.8 ± 15.4 | 57.0 ± 14.0 |
Female, n (%) | 8 (80) | 7 (70) |
RF positive, n (%) | 9 (90) | 9 (90) |
Anti-CCP Ab positive, n (%) | 9 (90) | 9 (90) |
CRP, mg/dl | 2.7 ± 2.1 | 2.9 ± 3.0 |
MTX, n (%) | 3 (30) | 4 (40) |
MTX dose, mg/week | 10.7 ± 3.1 | 7.0 ± 2.6 |
Glucocorticoid, n (%) | 9 (90) | 3 (30) |
Glucocorticoid dose, mg/day | 6.3 ± 5.4 | 6.5 ± 4.1 |
Previous Biologics, n (%) | 6 (60) | 6 (60) |
Infliximab, n (%) | 1 (10) | |
Etanercept, n (%) | 4 (40) | 3 (30) |
Adalimumab, n (%) | 2 (20) | 1 (10) |
Abatacept, n (%) | 2 (20) | |
DAS28CRP, mean ± SD | ||
Before | 3.91 ± 1.00 | |
After 24 weeks | 2.74 ± 1.00 | |
CDAI, mean ± SD | ||
Before | 16.5 ± 7.1 | |
After 24 weeks | 6.5 ± 5.3 |